Enhatch

Executive Summary

Enhatch is a pioneering digital health company that offers a cloud-based, AI-powered software platform for virtual surgical planning (VSP) in orthopedic and spine surgery. Founded in 2014 and headquartered in New York, the company addresses a critical bottleneck in the adoption of 3D-printed patient-specific implants and surgical guides. Its platform streamlines the entire workflow—from CT scan segmentation and implant design to collaboration between surgeons, engineers, and sales reps—reducing planning time from weeks to days. By integrating AI, Enhatch enhances accuracy and consistency while lowering the barrier to personalized surgical solutions. The company operates in the rapidly growing digital surgery market, estimated to exceed $10 billion by 2030, driven by demand for better outcomes, reduced complications, and cost efficiency. Enhatch’s software is device-agnostic and complements major 3D printing and implant manufacturers, positioning it as a key enabler in the shift toward customized care. Enhatch has likely secured early adopters among leading hospitals and medical device companies, though specific revenue and funding details are not public. The company faces competition from in-house VSP solutions and other startups, but its focus on AI and collaboration gives it a distinct edge. Given its niche in a high-growth vertical and the increasing regulatory acceptance of 3D-printed implants, Enhatch is well-positioned for expansion. Near-term catalysts include strategic partnerships with implant manufacturers, FDA clearance for AI-driven design features, and a potential Series B fundraising round. The conviction score reflects strong market tailwinds but tempered by the lack of disclosed traction and competitive pressures.

Upcoming Catalysts (preview)

• Q3 2026Partnership with a Major Orthopedic Implant Manufacturer70% success
• Q4 2026FDA Clearance for AI-Powered Segmentation Module60% success
• Q1 2027Series B Funding Announcement55% success